导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.52% | 1576/4699 |
| 近一周 | 0.72% | 93/5365 |
| 近一月 | 5.56% | 63/5324 |
| 近一季 | 5.17% | 284/5114 |
| 近半年 | 5.96% | 725/4837 |
| 近一年 | 3.75% | 1828/4300 |
| 近两年 | 40.45% | 1852/2924 |
| 近三年 | 50.11% | 532/2228 |
| 成立以来 | 100.36% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.57% 2823/4961 |
-8.19% 3855/5312 |
- - |
- - |
| 2025 | 11.09% 2765/4813 |
2.59% 1318/3635 |
11.53% 169/4076 |
-8.32% 4028/4524 |
5.90% 390/4813 |
| 2024 | 39.48% 23/3463 |
10.11% 73/2808 |
6.94% 110/3014 |
12.51% 2328/3129 |
5.29% 617/3463 |
| 2023 | -1.11% 493/2656 |
-2.38% 1971/2280 |
2.48% 139/2385 |
5.31% 92/2515 |
-6.13% 1640/2655 |
| 2022 | -3.72% 70/2207 |
2.20% 72/1919 |
-1.20% 1688/2016 |
-7.88% 151/2113 |
3.51% 680/2208 |
| 2021 | 1.61% 662/1822 |
10.54% 33/1255 |
-1.75% 1177/1330 |
-6.38% 923/1466 |
-0.06% 1191/1822 |
| 2020 | 11.15% 830/1250 |
-11.74% 850/1028 |
4.38% 908/1067 |
8.92% 691/1164 |
10.76% 581/1184 |
| 2019 | 29.65% 499/1092 |
15.81% 679/754 |
2.68% 74/804 |
-0.23% 587/850 |
9.28% 237/918 |
| 2018 | -10.98% 74/834 |
- - |
- - |
- - |
-9.08% 123/691 |
| 2017 | 20.97% 172/714 |
- - |
- - |
- - |
- - |
| 2016 | -1.82% 121/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 博时中证银行指数(LOF)A VS. 长安沪深300非周期A(740101) |